Search
EGS21
go.drugbank.com/drugs/DB05056ExperimentalGC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate … drug in the treatment of various immune mediated diseases, such as Crohn's disease, hepatitis, non-alcoholic steatohepatitis (NASH) or fatty liver and HIV.
INCB13739
go.drugbank.com/drugs/DB05064InvestigationalIt is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes
KIN-3248
go.drugbank.com/drugs/DB17587Investigationalmutations in the kinase domain of FGFR. … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.
Atractylodes japonica root oil
go.drugbank.com/drugs/DB11270ApprovedWithdrawnIt is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation.
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
ALT-2074
go.drugbank.com/drugs/DB05631InvestigationalAn organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. … BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.
3-Acetylpyridine Adenine Dinucleotide
go.drugbank.com/drugs/DB03363ExperimentalIt is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
Pipamperone
go.drugbank.com/drugs/DB09286InvestigationalIt was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518]. … In an effort to improve [haloperidol]'s pharmacological effects, Janssen discovered that pipamperone, an agent whose pharmacological profile was distinct from haloperidol and all other known antipsychotic
Mitemcinal
go.drugbank.com/drugs/DB06587InvestigationalMitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Cintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalThe IL13 portion binds to receptors on the tumor.